Analyst Price Targets — BAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 3:01 pm | — | Goldman Sachs | $17.00 | $20.54 | TheFly | Baxter price target lowered to $17 from $21 at Goldman Sachs |
| February 16, 2026 12:51 pm | Danielle Antalffy | UBS | $19.00 | $19.79 | TheFly | Baxter price target lowered to $19 from $21 at UBS |
| February 13, 2026 1:36 pm | — | Deutsche Bank | $20.00 | $19.23 | TheFly | Baxter price target lowered to $20 from $22 at Deutsche Bank |
| February 13, 2026 11:08 am | — | Barclays | $25.00 | $18.71 | TheFly | Baxter price target lowered to $25 from $30 at Barclays |
| February 12, 2026 8:55 pm | — | Jefferies | $19.00 | $18.71 | TheFly | Baxter price target lowered to $19 from $21 at Jefferies |
| February 12, 2026 8:43 pm | — | Stifel Nicolaus | $20.00 | $18.71 | TheFly | Baxter price target lowered to $20 from $22 at Stifel |
| January 9, 2026 12:19 pm | Matt Miksic | Barclays | $30.00 | $20.69 | TheFly | Baxter price target lowered to $30 from $36 at Barclays |
| January 9, 2026 10:46 am | — | Goldman Sachs | $23.00 | $20.69 | TheFly | Baxter price target raised to $23 from $22 at Goldman Sachs |
| January 5, 2026 2:46 pm | Vijay Kumar | Evercore ISI | $23.00 | $20.03 | TheFly | Baxter price target lowered to $23 from $24 at Evercore ISI |
| December 2, 2025 11:39 am | Patrick Wood | Morgan Stanley | $15.00 | $19.08 | TheFly | Baxter price target lowered to $15 from $19 at Morgan Stanley |
Latest News for BAX
Baxter International Inc. (BAX) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript
Our largest new purchase was Houston-headquartered Prosperity BancShares, the fifth-largest bank in Texas. Another notable purchase was Union Pacific, the largest freight railroad in the US. Besides our sale of Baxter International, we also exited LKQ, a vehicle parts distributor.
Baxter International Inc. (NYSE: BAX - Get Free Report) has been assigned a consensus rating of "Reduce" from the fourteen research firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to
Acquired 2,074,016 shares of Baxter International Inc; estimated trade value $39.63 million based on quarterly average prices Quarter-end position value rose by $39.63 million, reflecting both new shareholdings and price movement over the period Transaction resulted in a position representing 2.66% of 13F reportable assets under management (AUM) Position at quarter-end: 2,074,016 shares valued at $39.63 million This…
Baxter International faces a fundamental downturn after weak Q4 results and a dismal FY 2026 guide, prompting a hold rating downgrade. BAX trades at a very cheap valuation, but persistent margin compression, debt risks, and repeated earnings disappointments overshadow near-term recovery prospects. Despite some growth in Advanced Surgery and new connected care offerings, operational efficiency and profitability…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.